search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
News & numbers African vaccines


Africa has always imported the vast majority of its vaccines. Until recently, it looked like it had neither the will nor the opportunity to change that. Now, though, diffi culties sourcing Covid-19 vaccines, threats from continent-specifi c outbreaks, rising demand from a fast-growing population and technological developments pushing down manufacturing costs might just ignite the continent’s industry.


Percentage of Africa’s vaccines that are currently imported from outside the continent


99%


13 22


Number of vaccine products that are fi lled and fi nished in Africa


scale, which means lower effi ciencies and higher costs


6


Number of vaccine products that are imported for distribution across Africa by African companies†


$1.4bn


High-end estimate of the African vaccine market


Value of the current African vaccine market


$5.4bn


by 2030 – depending on the requirement for Covid-19 boosters and the introduction of vaccines for malaria and HIV


2030 1.2 billion doses 2.4


Number of vaccine products that are


15 packaged on the continent, mainly in Egypt, South Africa and Senegal Estimated potential public market value by 2030, by scenario (in $ billion)


Conservative cases: High likelihood products only


+7%per annum Assumptions


Legacy and expanding routine products get wider coverage and new country introductions


Malaria vaccine (RTS,S) is introduced: $2/dose


No novel products are introduced or licensed


Ebola stockpile is 500,000 doses, replaced biennially


Covid-19 does not require continued immunization beyond 20301


Midcases: Expanded portfolio with slightly higher pricing assumptions


+12%per annum Assumptions


4.3


Legacy and expanding routine products get wider coverage and new country introductions


Gavi-transitioning2 pay higher prices


countries


Malaria vaccine (RTS,S) is introduced: $5/dose


Some novel outbreak products (for example, for Lassa fever or chikungunya) are licensed with low demand (100,000 doses per annum)


HIV vaccine is licensed and introduced in high-prevalence (>10%) countries


Covid-19 vaccination boosters required every ten years


2030 1.3 billion doses 2030 1.5 billion doses


Notes: These forecasts are not exhaustive; they do not necessarily incorporate the full range of products in development (such as new dosage forms or full range of candidates). 1


middle-income countries. Source: Interviews with industry experts; Linkbridge; McKinsey & Company analysis.


These conservative assumptions were refined with a group of vaccine experts; the actual market may be substantially larger if Covid-19 becomes endemic (and requires repeated vaccinations, for example). 2


The public market of Covid-19 vaccines may vary significantly from country to country, as there is no global consensus on long-term vaccination strategies. Gavi, the Vaccine Alliance, is a public–private global health partnership focused on providing immunisation access to low and


High end: Novel portfolio with slightly higher pricing assumptions


5.4


+14%per annum Assumptions


Existing products (legacy and routine) at higher prices as per midcase scenario


Malaria vaccine (RTS,S) is introduced: $10/dose


Some novel outbreak products (for example, for Lassa fever or chikungunya) are licensed with medium demand (250,000 doses per annum)


HIV vaccine is licensed and introduced in medium- and high-prevalence countries (>3% prevalence)


Covid-19 vaccination boosters are required every two years, for vulnerable populations


Number of vaccine substances that are manufactured in Africa currently – typically at small


†Does not include branches of foreign companies in Africa that solely import for distribution.


Source: McKinsey & Company


World Pharmaceutical Frontiers / www.worldpharmaceuticals.net


7


Cienpies Design; davorana; doom.ko/Shutterstock.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53